# Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

> **NCT04771572** · PHASE1 · RECRUITING · sponsor: **Newave Pharmaceutical Inc** · enrollment: 100 (estimated)

## Conditions studied

- Non Hodgkin Lymphoma
- Richter Transformation
- Multiple Myeloma
- T-cell-prolymphocytic Leukemia
- Acute Myeloid Leukemia
- Acute Lymphocytic Leukemia
- Myeodysplastic Syndrome
- Myelodysplastic/Myeloproliferative Neoplasm
- Myelofibrosis
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Chronic Myelomonocytic Leukemia-2
- Myelodysplastic Neoplasm in Blast Phase

## Interventions

- **DRUG:** LP-118

## Key facts

- **NCT ID:** NCT04771572
- **Lead sponsor:** Newave Pharmaceutical Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-05-08
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04771572

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04771572, "Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04771572. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*